Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastrointest Pharmacol Ther. Aug 6, 2014; 5(3): 156-168
Published online Aug 6, 2014. doi: 10.4292/wjgpt.v5.i3.156
Published online Aug 6, 2014. doi: 10.4292/wjgpt.v5.i3.156
AKIN criteria | Urine output | RIFLE criteria | |
Serum creatinine | (common to both AKIN and RIFLE) | Class | Serum creatinine or GFR |
Stage 1 | |||
Increase of more than or equal to 0.3 mg/dL (≥ 26.5 μmol/L) or increase to more than or equal to 150% to 199% (1.5- to 1.9-fold) from baseline | Less than 0.5 mL/kg per hour for more than 6 h | Risk | Increase in serum creatinine × 1.5 or GFR decrease > 25% |
Stage 2 | |||
Increased to more than 200% to 300% (≥ 2- to 2.9-fold) from baseline | Less than 0.5 mL/kg per hour for more than 12 h | Injury | Serum creatinine × 2 or GFR decreased > 50% |
Stage 3 | |||
Increased to more than 300% (≥ 3-fold) from baseline, or more than or equal to 4.0 mg/dL (≥ 354 μmol/L) with an acute increase of at least 0.5 mg/dL (44 μmol/L) or on RRT | Less than 0.3 mL/kg per hour for 24 h or anuria for 12 h | Failure | Serum creatinine × 3, or serum creatinine > 4 mg/dL (> 354 μmol/L) with an acute rise > 0.5 mg/dL (> 44 μmol/L) or GFR decreased > 75% |
Loss | Persistent acute renal failure = complete loss of kidney function > 4 wk | ||
End-stage kidney disease | ESRD > 3 mo |
- Citation: Pipili C, Cholongitas E. Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther 2014; 5(3): 156-168
- URL: https://www.wjgnet.com/2150-5349/full/v5/i3/156.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v5.i3.156